Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03540381
Other study ID # KobeU-152M816M
Secondary ID
Status Completed
Phase
First received
Last updated
Start date May 1, 2011
Est. completion date July 31, 2017

Study information

Verified date May 2018
Source Kobe University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The aim of this study is to evaluate the relation among cholesterol uptake capacity which measure HDL functionality, neoathrosclerosis and target-lesion revascularization.


Description:

Intracoronary stent implantation has markedly reduced the incidence of restenosis in patients with coronary artery disease. However, in-stent restenosis requiring target-lesion revascularization (TLR) occurs even with the use of drug-eluting stents. Emerging evidence suggests that among various potential risk factors, atherogenic progression within the neointima, "neoatherosclerosis" is one of the major contributors to TLR, and that patients' lipid profile is one of the key risk factors for the development of neoatherosclerosis.

Conversely, recent animal and human studies have demonstrated the importance of high-density lipoprotein (HDL) functionality, rather than of HDL-cholesterol levels, in the development of de novo coronary artery disease. Cholesterol efflux capacity, a measure of the ability of HDL to promote cholesterol removal from lipid-laden macrophages, was found to be inversely correlated with the incidence of cardiovascular events and was shown to improve cardiovascular risk prediction beyond that with the use of traditional coronary risk factors. Therefore, the investigators hypothesized that the HDL function of promoting cholesterol removal from lipid-laden macrophages could be associated with TLR through its effect on the process of neoatherosclerosis progression within stents.

Recently, the investigators developed a rapid cell-free assay system to directly evaluate the capacity of HDL to accept additional cholesterol; the measurement of this cholesterol uptake capacity (CUC) enables HDL functionality to be readily evaluated in our daily practice. Thus, the investigators performed this study in order to clarify the potential relationship among CUC, neoatherosclerosis, and TLR by using the novel cell-free assay system, CUC measurement, and optical coherence tomography (OCT) analysis.


Recruitment information / eligibility

Status Completed
Enrollment 181
Est. completion date July 31, 2017
Est. primary completion date July 31, 2017
Accepts healthy volunteers No
Gender All
Age group 20 Years to 85 Years
Eligibility Inclusion Criteria:

- Clinical diagnosis of coronary artery disease

- Patients who had undergone percutaneous coronary intervention

- Patients who had been treated with bare-metal stents, drug-eluting stents

- Patients who had successfully undergone follow-up OCT for the target stents >6 months after stenting.

Exclusion Criteria:

- The stent was implanted in the left main trunk

- OCT images were of insufficient quality

Study Design


Related Conditions & MeSH terms


Intervention

Other:
neoatherosclerosis


Locations

Country Name City State
Japan Kobe University Graduate School of Medicine, Department of Cardiology Kobe Hyogo

Sponsors (1)

Lead Sponsor Collaborator
Kobe University

Country where clinical trial is conducted

Japan, 

Outcome

Type Measure Description Time frame Safety issue
Primary Cholesterol Uptake Capacity (CUC) CUC is a new rapid cell-free assay system to evaluate the functional capacity of HDL to accept additional cholesterol an average of a year and a half
See also
  Status Clinical Trial Phase
Recruiting NCT05462262 - Intensive Lipid-lowering for Plaque and Major Adverse Cardiovascular Events in Low to Intermediate 10-year ASCVD Risk Population N/A
Not yet recruiting NCT06040073 - Natural History of Coronary Atherosclerosis
Active, not recruiting NCT03349385 - Registry of Secondary Revascularization
Recruiting NCT05860400 - Efficacy and Safety of Comprehensive Treatment in Patients With IR-CAD: a Self-controlled Cohort Study
Recruiting NCT05783804 - Plaque Reversal With Early, Aggressive Lipid Lowering Therapy
Completed NCT03192579 - Effect of Rosuvastatin and Eicosapentaenoic Acid on Neoatherosclerosis: The LINK-IT Trial Phase 4
Completed NCT03195621 - Critical Treatment of Coronary Artery Disease N/A
Recruiting NCT05800093 - Proteomics and Genomics Combined With CT to Predict CVD
Recruiting NCT03533959 - To Evaluate the Efficacy of Alirocumab for Neoatherosclerosis by Using OCT, in Comparison With Standard Statin Therapy
Recruiting NCT04772768 - Prior CABG Patients Evaluated for Saphenous VeIn grAft DysfUnction and Progression of Coronary arTery Disease
Not yet recruiting NCT06007248 - Disease Characteristics of IR-CAD: a Case-control Study
Recruiting NCT03943459 - Sirtuin-1 and Advanced Glycation End-products in Postmenopausal Women With Coronary Disease Phase 3
Recruiting NCT03788369 - Evaluation of Effectiveness and Safety of Hybrid Coronary Revascularization